These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38430074)

  • 21. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.
    Ruiz Garcia Y; Abitbol V; Pellegrini M; Bekkat-Berkani R; Soumahoro L
    Infect Dis Ther; 2022 Apr; 11(2):639-655. PubMed ID: 34591258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).
    Croxtall JD; Dhillon S
    Drugs; 2012 Dec; 72(18):2407-30. PubMed ID: 23231026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meningococcal vaccination in patients with newly diagnosed asplenia in the United States.
    Ghaswalla PK; Bengtson LGS; Marshall GS; Buikema AR; Bancroft T; Schladweiler KM; Koep E; Novy P; Hogea CS
    Vaccine; 2021 Jan; 39(2):272-281. PubMed ID: 33309081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Awareness, attitudes, and practices on meningococcal serogroup B vaccination in the United States among parents of older adolescents and among young adults.
    Herrera-Restrepo O; Zhou Z; Krishnan A; Conley WJ; Oladele E; Multani JK; Tuly R; Shi L; Chen CC; Preiss S; Clements DE
    Curr Med Res Opin; 2024 Jan; 40(1):125-140. PubMed ID: 38032143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine - United States, 2014-2018.
    Blain AE; Reese HE; Marjuki H; Topaz N; Mbaeyi S; McNamara LA
    Vaccine; 2021 Dec; 39(52):7541-7544. PubMed ID: 34802785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth.
    Warshaw MG; Siberry GK; Williams P; Decker MD; Jean-Philippe P; Lujan-Zilbermann J
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e69-e74. PubMed ID: 28339668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serogroup B meningococcal vaccination practice patterns on college campuses.
    Haimowitz R; Torres R; Caleb S; Thompson D; Smith A; Ciotoli C; Dannenbaum M; Fu LY
    Vaccine; 2020 Oct; 38(46):7350-7356. PubMed ID: 33010977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.
    Beran J; Dražan D; Enweonye I; Bhusal C; Toneatto D
    mSphere; 2021 Dec; 6(6):e0055321. PubMed ID: 34787449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
    Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
    Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implementation Experience With Meningococcal Serogroup B Vaccines in the United States: Impact of a Nonroutine Recommendation.
    Fergie J; Howard A; Huang L; Srivastava A
    Pediatr Infect Dis J; 2021 Mar; 40(3):269-275. PubMed ID: 33565815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Epidemiology and Trends in Meningococcal Disease-United States, 1996-2015.
    MacNeil JR; Blain AE; Wang X; Cohn AC
    Clin Infect Dis; 2018 Apr; 66(8):1276-1281. PubMed ID: 29126310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parental awareness of Meningococcal B vaccines and willingness to vaccinate their teens.
    Basta NE; Becker AB; Li Q; Nederhoff D
    Vaccine; 2019 Jan; 37(4):670-676. PubMed ID: 30587431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age.
    Marshall GS; Pelton SI; Robertson CA; Oster P
    Hum Vaccin Immunother; 2022 Nov; 18(6):2099142. PubMed ID: 35947774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults.
    Presa J; Burman C; Tort MJ; Cane A; Bocchini JA
    Hum Vaccin Immunother; 2023 Dec; 19(1):2212570. PubMed ID: 37257838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2019.
    Elam-Evans LD; Yankey D; Singleton JA; Sterrett N; Markowitz LE; Williams CL; Fredua B; McNamara L; Stokley S
    MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(33):1109-1116. PubMed ID: 32817598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations.
    Baker CJ
    J Adolesc Health; 2016 Aug; 59(2 Suppl):S29-37. PubMed ID: 27449147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
    Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
    Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
    J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.